Page last updated: 2024-09-02

carboxyamido-triazole and thalidomide

carboxyamido-triazole has been researched along with thalidomide in 2 studies

Compound Research Comparison

Studies (carboxyamido-triazole)	Trials (carboxyamido-triazole)	Recent Studies (post-2010) (carboxyamido-triazole)	Studies (thalidomide)	Trials (thalidomide)	Recent Studies (post-2010) (thalidomide)
105	15	22	9,789	1,385	4,342

Protein Interaction Comparison

Protein	Taxonomy	thalidomide (IC50)
Cereblon isoform 4	Magnetospirillum gryphiswaldense	7.8
Prostaglandin G/H synthase 1	Ovis aries (sheep)	0.37
Prostaglandin G/H synthase 2	Ovis aries (sheep)	0.5
DNA damage-binding protein 1	Homo sapiens (human)	1.38
Protein cereblon	Homo sapiens (human)	1.38

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kuwano, M; Ono, M	1
Libutti, SK; Zogakis, TG	1

Reviews

2 review(s) available for carboxyamido-triazole and thalidomide

Article	Year
[Development of anti tumor agents targeting angiogenesis]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured	1997
General aspects of anti-angiogenesis and cancer therapy. Expert opinion on biological therapy, 2001, Volume: 1, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endostatins; Endothelial Growth Factors; Fatty Acids, Unsaturated; Humans; Interleukin-12; Lymphokines; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Receptors, Vitronectin; RNA, Catalytic; Sesquiterpenes; Suramin; Thalidomide; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001

Article

Year

[Development of anti tumor agents targeting angiogenesis].

Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:2

Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured

1997

General aspects of anti-angiogenesis and cancer therapy.

Expert opinion on biological therapy, 2001, Volume: 1, Issue:2

Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endostatins; Endothelial Growth Factors; Fatty Acids, Unsaturated; Humans; Interleukin-12; Lymphokines; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Receptors, Vitronectin; RNA, Catalytic; Sesquiterpenes; Suramin; Thalidomide; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001